May 17th 2024
Tarlatamab is a first-in-class immunotherapy that binds to DLL3 tumor cells and CD3 T-cells, to kill DLL3-expressing SCLC.
FDA Accepts Supplemental New Drug Application for Tapinarof Cream, 1%, in Atopic Dermatitis
April 29th 2024The acceptance is based on positive data from the phase 3 ADORING 1 and ADORING 2 pivotal trials, as well as interim results from the phase 3 ADORING 3 open-label, long-term extension trial.
Read More
FDA Approves Pivmecillinam for Treatment of Female Adults With Urinary Tract Infections
April 24th 2024Pivmecillinam (Pivya; UTILITY therapeutics Ltd) tablets were approved for female adults with uncomplicated urinary tract infection caused by Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
Read More